Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up reaching 15 months total. The trial design, including a randomized withdrawal phase, was built to assess both efficacy and durability of effect in a condition where existing medications frequently fall short. Results from this level of clinical evidence carry meaningful weight for patients and clinicians considering cannabis-based options for chronic low back pain management.
#2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence on cannabis extract efficacy for chronic low back pain, a condition affecting over 500 million people globally where current pharmacotherapies demonstrate inadequate pain relief with significant adverse effect profiles. The 12-week double-blind design with 820 participants and 6-month extension phase establishes the safety and efficacy profile necessary for clinicians to make evidence-based decisions regarding cannabis as an alternative to conventional analgesics and opioids in CLBP management. Given the opioid crisis and limited efficacy of existing treatments, demonstrated efficacy of VER-01 would provide a potentially safer therapeutic option with a more favorable risk-benefit
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial adds meaningful evidence to the cannabis literature for chronic low back pain, a condition where conventional pharmacotherapy often falls short, though several design considerations warrant careful interpretation. The 12-week double-blind phase provides robust data on efficacy and tolerability, but the mechanism of action in DKJ127’s full-spectrum extract remains incompletely characterized, making it difficult to predict individual patient response or optimize dosing strategies. Notably, the open-label extension phase may introduce bias regarding long-term safety and efficacy profiles, and we lack clarity on whether benefits persist beyond the initial treatment window or how this extract compares to other cannabis formulations already available to patients. Despite these limitations, if efficacy and safety data support approval, VER-01 could offer a non-opioid, potentially lower-risk option for selected patients with CLBP who have failed conventional approaches, provided we establish clear patient selection criteria and implement appropriate monitoring for cannabinoid-related side effects and drug interactions in clinical practice.